loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Sequent Scientific Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Sequent Scientific Ltd. 08 Aug 2025 13:22 PM
Result PDF

Q1FY26 Quarterly Result Announced for Sequent Scientific Ltd.

Pharmaceuticals company Sequent Scientific announced Q1FY26 results

  • Revenues: Rs 4,414 million compared to Rs 3,902 million during Q1FY25, change 13.1%.
  • EBITDA: Rs 602 million compared to Rs 483 million during Q1FY25, change 24.7%.
  • EBITDA Margin: 13.6% for Q1FY26.
  • PAT: Rs 176 million compared to Rs 91 million during Q1FY25, change 93.7%.

Rajaram Narayanan, Managing Director, said: “This quarter reinforces the momentum that we have built over the last 18 months, as we continue to deliver higher growth and profitability across all parts of the business. This has come on the back of initiatives in the areas relating to superior product mix, new launches and improved operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan and we expect all regulatory requirements to be completed in the next few months. We have commenced working on the Sequent 3.0 roadmap to leverage the synergies resulting from the merger and accelerate profitable revenue growth.”

Result PDF

Result PDF

Pharmaceuticals company Sequent Scientific announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue stood at Rs 4,017 million, a growth of 11.2% YoY
  • EBITDA rose to Rs 569 million, increasing by 38.7% YoY
  • EBITDA Margin expanded by 280 bps, reaching 14.2% (vs. 11.4% in Q4FY24)

FY25 Financial Highlights:

  • Revenue came in at Rs 15,514 million, up 13.3% YoY
  • EBITDA surged to Rs 1,993 million, marking a strong 86.6% YoY growth
  • EBITDA Margin improved by 500 bps, rising to 12.8% (vs. 7.8% in FY24)

Commenting on the Company’s performance, Rajaram Narayanan, Managing Director stated “This quarter reinforces the momentum that we have built in the business over the last 18 months. The significant improvement in profitability metrics and double-digit revenue growth has come on the back of several initiatives which have helped deliver a superior product mix, accelerate launches and improve operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan. The strong performance in FY 24-25 marks a turning point for us, as we prepare to accelerate the growth of the company and create the foundation for the Sequent 3.0 journey.”

Result PDF

Pharmaceuticals company Sequent Scientific announced Q4FY24 & FY24 results:

  • Highest EBITDA (pre-ESOP cost) in twelve quarters at Rs 411 million; Pre-ESOP cost EBITDA growth of 36% / 221% QoQ / YoY
  • 11.4% EBITDA margin – expanded by 220 / 790 bps QoQ / YoY
  • Q4FY24 Revenue 9.7% QoQ reported ( 7.5% in constant currency ) API business 39% QoQ; FY24 Revenue -3.6% YoY reported
  • Growth for continuing business and post Turkey currency accounting adjustments at 6% YoY reported ( 11% in constant currency) in Q4; FY24 Revenue 1.5% YoY reported

Rajaram Narayanan, MD & CEO, said "It gives me immense satisfaction to share that our transformation program, which began late last year, has continued to deliver according to plan. In Q4FY24, the company achieved its highest EBITDA (pre-ESOP costs) in the last 12 quarters of Rs 411 million. The EBITDA margin for Q4FY24 at 11.4% is in line with our target to exit FY24 with double-digit EBITDA margins. Revenues for the quarter Q4FY24 grew sequentially at 7% in constant currency, and 2% on a reported basis. Adjusting for discontinued business units and currency accounting adjustments in Turkey, our revenues grew 6% YoY in Rs terms and 11.4% in constant currency terms, setting the base for higher growth in the coming year.

I am particularly pleased to share the strong performance delivered by our API business this quarter – 39% sequential increase in API revenues combined with sustained segment margin improvement. This is the outcome of our focus on the quality of business combined with operational excellence initiatives undertaken under Project Pragati. Our stable base of business in regulated markets has allowed us to selectively participate in promising semi-regulated markets witnessing growing volumes. During the quarter, we filed 2 new products, one each in the companion and production animal segments, the commercialization for which too is now expected to pick up. The company has also completed WHO audits and is preparing to get prequalified for WHO supplies.

Despite seasonality factors that affect the Jan-March period, our formulations geographies continued to perform well during Q4FY24, led by strong YoY growth in Europe ( 8%) and India ( 9%). The proactive pricing and portfolio actions in Turkey continue to support margin growth. Some emerging markets in North Africa and Middle East have seen currency issues, delaying execution of a few orders. We are accelerating our initiatives on margin improvement and new business development across all markets. We have already started expanding our footprint in India and should see results from mid-year.

We continue to evaluate inorganic actions for strategic growth in formulations and APIs, to support our operations and emerge as a larger participant in the growing Animal Health industry."

Result PDF

 Pharmaceutical company SeQuent Scientific announced Q2FY23 results:

  • Revenues Rs 3,376 million in Q2FY23 and Rs 6,789 million in H1FY23
  • EBITDA (pre-ESOP) Rs 150 million in Q2FY23 and Rs 351 million in H1FY23
  • EBITDA Rs 51 million in Q2FY23 and Rs 161 million in H1FY23

Rajaram Narayanan, Managing Director, stated, “Q2FY23 has been challenging owing to macro environment headwinds even though we continue to see strong performance in select markets. While the overall business grew 2.9% in constant currency terms, the reported revenue declined 3.7% over Q2FY22. EBITDA before ESOP costs stood at Rs 150 million for Q2. Normalised margins (after one-time costs & currency impact) are trending upwards.

The API business was subdued due to a slower revival in demand and delays in concluding a few contracts. Our efforts in developing strong partnerships with the top 10 animal health global companies are yielding results and we are confident to restore momentum in this business. We continue to invest in API business across key projects and upgrade our facilities. Our Mahad facility received the prestigious EcoVadis Sustainability Silver Medal and certificate, following by the recent TÜV Nord ISO certifications for Environment, Health & Safety (EHS) in Q1, further validating our commitment to global EHS standards.

Our Formulations business grew by 14.8% on constant currency basis, driven by a strong performance in emerging markets and India. We continue to accelerate our efforts in these markets while simultaneously implementing profitability improvement initiatives in our businesses in Europe & Turkey. We continue to believe in SeQuent’s robust business model and are executing on key growth levers.

We are pleased to announce that we signed a definitive agreement on November 7, 2022, to acquire 100% stake in Tineta Pharma Pvt Ltd, a company incorporated in India. This acquisition, which is in line with our strategic priority to scale up India formulations business, will be EBITDA accretive and gives a significant boost to our SeQuent 2.0 plans.

While the business environment is challenging due to high input costs, currency deterioration in some markets and subdued demand, the company is undertaking multiple initiatives to prioritise growth segments, remain competitive on costs and deepen our engagement with customers. We continue to invest in capabilities and talent required to deliver our ambitious plans and are confident that our initiatives would create a sustainable, long-term advantage for the company as it returns to higher levels of profitable growth.”

 

Result PDF

Pharmaceuticals firm Sequent Scientific announced Q1FY23 Result :

  • Revenues at Rs 3,413 Million, up by 6.5%, Latam and Formulations drive growth

Commenting on the Company’s performance, Rajaram Narayanan, Managing Director stated “Our overall sales in Q1 FY 23 grew 6.5% compared to corresponding quarter last year, reflecting a strong, resilient performance in a challenging environment. We continue to progress on our strategy to build a sustainable global business in the area of animal health. The Formulations segment grew 19.5% on constant currency basis, driven by a strong performance in Brazil, within the overall Emerging Markets region. The API business results however, are subdued owing to the exceptional impact of the fire incident at our Vizag plant in May, which hampered operations for a few days.

We have now restored the operations in full and are geared to complete the backlog of shipments over the rest of the year. The macro environment will remain challenging on account of volatility in currencies and sustained inflationary cost pressures in raw materials and utilities. However, with our concerted efforts in engaging our long-term partners, cautious price increases, and initiatives on cost management, we expect acceleration in the second half of this financial year.

We continue to invest in deepening our partnerships with global players, upgrading our manufacturing facilities, expanding the product pipeline and developing our people.”

Result PDF

Pharmaceuticals firm Sequent Scientific declares Q4FY22 result:

  • Q4 FY22 Revenues at Rs 3,837 Million, FY22 Revenues at Rs 14,128 Million
  • Q4 FY22 Revenues at Rs 3.83 Bn ; 11.7% cc
  • API: Q4 strong performance at Rs 1.27 Bn, 11% cc
  • Formulations at  Rs 2.56 Bn , 12.0% cc
  • Latam, India & EMs drive strong growth
  • India business crosses Rs 1 Bn sales milestone
  • Q4 revenues of Rs 2.56 Bn, 12 % YoY cc growth
  • Met expectations of double-digits growth (cc) for full year, enabled by a diversified market reach
  • India business achieves key milestone, crosses landmark of Rs 1 Bn revenues for the year
  • Europe weakness owing to supply chain pressures and slowdown in demand
  • Surprises in currency volatility impact Turkey growth, uncertainty likely to continue in near future

 

Result PDF

Pharmaceuticals firm Sequent Scientific declares Q3FY22 result:

  • Revenues at Rs 3,580 Million, PAT after minority interest at Rs 171 Million

Commenting on the Company’s performance, Manish Gupta, Managing Director stated “Q3 reflects the beginning of a recovery in business across both APIs and formulations. We saw a strong growth in our formulations business, which grew 18.5% on constant currency basis, driven by scale up across our key markets - Brazil, India, and Turkey. On API side, we had strong orderbook & dispatches. However, port congestion challenges impacted ~15% of dispatches, depressing revenues, and thereby overall profitability.

While the cost environment continues to be concerning for the industry, our concerted efforts towards price increases have started reflecting in our financial performance and we expect to see full benefit from Q4 FY22. Performance in Turkey in a volatile currency environment is significant. Our robust manufacturing footprint in the country makes us extremely confident of our continuing growth in local and export markets. Overall, we stay extremely confident of our unique, multi-pillar business model and envisage strong recovery in Q4 led by our API business and normalization of performance across revenues and profitability in FY23.”

 

Result PDF

Financial Highlights:

  • Revenues at Rs. 3,506 Million
  • PAT after minority interest at Rs. 143 Million
  • PAT margin at 4.1%

Commenting on the Company’s performance, Manish Gupta, Managing Director stated “The current quarter though muted compared to corresponding quarter last year, reflects a growth of 10% as compared to the previous quarter. We saw a sharp recovery in our API business, which saw 21% growth vs Q1 FY22 driven by 25% growth in API portfolio (ex-Albendazole) while our formulation business continues to deliver consistent growth across geographies.

While the cost environment is concerning for the industry, we have initiated concerted efforts to mitigate the impact of the same. We expect these to start reflecting in our margins in the coming quarter with full benefit from Q4 FY22.

We are achieving significant progress in expanding our portfolio through value-added arrangements for vaccines in Turkey and India and have recently concluded another long-term agreement with a top-10 animal health company. 

Despite a challenging first half of the year, we look at the second half of FY22 with increased confidence as we start reaping benefits from our recent initiatives and deliver a near double-digit growth for the business despite a flat API business for the year.” 

 

 

Result PDF

Revenues at Rs 3,205 Million up by 8.6%, Operating EBITDA at Rs 358 Million

Commenting on the Company’s performance, Manish Gupta, Managing Director stated “The quarter gone by has indeed been the most challenging one, both from demand and execution perspective. We are pleased to report an over 15% growth in our formulations business even as our API business reported a de-growth after many quarters of consistent growth. We reported revenues of Rs 320 Crores for the quarter, reflecting a growth of 8.9% YOY on constant currency basis while the EBITDA stood at Rs 35.8 Crores excluding ESOP costs.

On the business side, we are pleased with continuing strong growth in the key markets of India & LATAM, and we expect improved performance in Europe and Turkey going forward. We shall continue to invest both in expanding our footprints as well as strengthening our presence in existing markets.

We expect strong recovery in our API business in the second half. Our strategy for API business continues to play out well as we continue to improve the quality of business with ever increasing contribution of regulated markets business, which now stands at 72% vs. 66% last year.

Despite a slower start to the year, we stay confident and on track of achieving our financial and strategic objectives for the year.”

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status